Drug Profile


Alternative Names: AAV2-CB-RS1; BIIB087; rAAV hRS1; rAAV2tYF CB hRS1; Recombinant adeno associated virus vector expressing retinoshcisin; X-linked retinoschisis gene therapy-AGTC; XLRS gene therapy

Latest Information Update: 16 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Applied Genetic Technologies Corporation
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action Gene transference; RS1 gene expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinoschisis
  • New Molecular Entity No

Highest Development Phases

  • Phase II Retinoschisis

Most Recent Events

  • 12 Apr 2018 Applied Genetic Technologies Corporation completes enrolment in its phase I/II trial for X-linked Retinoschisis in USA
  • 10 May 2017 Safety data from a phase I/II trial in Retinoschisis released by Applied Genetics Technology Corporation
  • 10 Jun 2016 Phase-II clinical trials in Retinoschisis in USA (Intravitreous)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top